Business Description
Insmed is a biopharmaceutical company focused on developing treatments for people living with serious and rare diseases, operating across the United States, Europe, Japan, and other markets worldwide. Its flagship product, ARIKAYCE, treats a difficult-to-cure type of lung infection, while its pipeline includes brensocatib, an oral drug being studied for bronchiectasis and other inflammatory conditions, along with inhaled therapies targeting rare lung diseases such as pulmonary hypertension. The company is also advancing gene therapies for Duchenne muscular dystrophy and ALS, supported by early-stage research in areas such as AI-driven protein engineering and RNA technology. Founded in 1988 and based in Bridgewater, New Jersey, Insmed continues to grow its portfolio with the goal of addressing conditions that have few or no existing treatment options.
